Results 11 to 20 of about 4,742,503 (345)

Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study

Journal of Clinical Oncology, 2022
PURPOSE Pembrolizumab demonstrated durable antitumor activity in patients with previously treated, advanced microsatellite instability–high or mismatch repair–deficient (MSI-H/dMMR) tumors, including endometrial cancer, in the nonrandomized, open-label ...
D. O’Malley, G. Bariani, P. Cassier, A. Marabelle, A. Hansen, A. de Jesus Acosta, W. Miller, T. Safra, A. Italiano, L. Mileshkin, Lei Xu, F. Jin, K. Norwood, M. Maio   +13 more
semanticscholar   +1 more source

Hypoxia and hyperglycaemia determine why some endometrial tumours fail to respond to metformin [PDF]

, 2020
High expression of Ki67, a proliferation marker, is associated with reduced endometrial cancer-specific survival. Pre-surgical metformin reduces tumour Ki-67 expression in some women with endometrial cancer. Metformin's anti-cancer activity may relate to
Crosbie, EJ, Finegan, KG, Kitson, S, Latif, A, Lisanti, MP, Marshall, K, McVey, R, Sivalingam, VN, Sotgia, F, Stratford, IJ   +9 more
core   +2 more sources

Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program

International Journal of Gynecological Cancer, 2022
Background The endometrial cancer molecular classification has been integrated into the 2020 World Health Organization (WHO) diagnostic classification and European treatment guidelines, and provides direction towards more effective and less toxic ...
Rainbo Research, Consortium, Gynecological Cancer   +2 more
semanticscholar   +1 more source

Current and Emerging Prognostic Biomarkers in Endometrial Cancer

Frontiers in Oncology, 2022
Endometrial cancer is the most common gynaecological malignancy in high income countries and its incidence is rising. Whilst most women with endometrial cancer are diagnosed with highly curable disease and have good outcomes, a significant minority ...
K. Njoku, Chloe E. Barr, E. Crosbie
semanticscholar   +1 more source

Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta‐analysis

Cancer, 2021
Endometrial cancers (ECs) with somatic mutations in DNA polymerase epsilon (POLE) are characterized by unfavorable pathological features, which prompt adjuvant treatment.
J. McAlpine, D. Chiu, R. Nout, D. Church, Pascal Schmidt, S. Lam, S. Leung, S. Bellone, Adele Wong, S. Brucker, Cheng-Han Lee, B. Clarke, D. Huntsman, M. Bernardini, J. Ngeow, A. Santin, P. Goodfellow, D. Levine, M. Köbel, S. Kommoss, T. Bosse, C. Gilks, A. Talhouk   +22 more
semanticscholar   +1 more source

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy

Journal of Clinical Oncology, 2020
PURPOSE The randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy (CTRT) versus radiotherapy alone (RT) for ...
A. Léon-Castillo, S. D. de Boer, M. Powell, L. Mileshkin, H. Mackay, A. Leary, H. Nijman, N. Singh, P. Pollock, P. Bessette, A. Fyles, C. Haie-meder, V. Smit, R. Edmondson, H. Putter, H. Kitchener, E. Crosbie, M. de Bruyn, R. Nout, N. Horeweg, C. Creutzberg, T. Bosse   +21 more
semanticscholar   +1 more source

New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines

Cancers, 2021
Simple Summary Histopathological classification of endometrial carcinoma has evidenced two main groups with different biological behavior: low-grade (G1–G2) and high-grade (G3) endometrial tumors.
A. Santoro, G. Angelico, A. Travaglino, F. Inzani, D. Arciuolo, M. Valente, N. D'Alessandris, G. Scaglione, V. Fiorentino, A. Raffone, G. Zannoni   +10 more
semanticscholar   +1 more source

Mutations and amplification of oncogenes in endometrial cancer [PDF]

, 1999
Alterations in oncogenes are critical steps in the development of endometrial cancer. To investigate the potential clinical relevance of the amplification of the oncogenes c-erbB2, c-myc, and int-2 and the mutation of K-ras in endometrial cancer, 112 ...
An, Han-Xiang, Beckmann, Matthias W., Bender, Hans G., Cho, Yong-Jig, Hantschmann, Peer, Niederacher, Dieter   +5 more
core   +1 more source

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

Journal of Clinical Oncology, 2020
PURPOSE Patients with advanced endometrial carcinoma have limited treatment options. We report final primary efficacy analysis results for a patient cohort with advanced endometrial carcinoma receiving lenvatinib plus pembrolizumab in an ongoing phase Ib/
V. Makker, Matthew H. Taylor, C. Aghajanian, A. Oaknin, J. Mier, A. Cohn, M. Romeo, R. Bratos, M. Brose, C. DiSimone, M. Messing, D. Stepan, C. Dutcus, Jane Wu, E. Schmidt, R. Orlowski, P. Sachdev, R. Shumaker, A. Casado Herráez   +18 more
semanticscholar   +1 more source

Molecular Basis of Endometriosis and Endometrial Cancer: Current Knowledge and Future Perspectives

International Journal of Molecular Sciences, 2021
The human endometrium is a unique tissue undergoing important changes through the menstrual cycle. Under the exposure of different risk factors in a woman’s lifetime, normal endometrial tissue can give rise to multiple pathologic conditions, including ...
M. Terzic, G. Aimagambetova, J. Kunz, G. Bapayeva, B. Aitbayeva, S. Terzic, A. Laganà   +6 more
semanticscholar   +1 more source